ALRN | Aileron Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.5900 - 3.11
52 Week Range	1.6100 - 7.42
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	114,645
Average Volume	77,163
Shares Outstanding	21,665,900
Market Cap	59,797,884
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-06-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.96
Forward P/E Ratio	N/A
EPS	-2.88
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	15
Country	USA
Website	ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

ALRN's peers: ADIL, AMTI, CBIO, BPTH, BNTC, ARTL, HSTO, CRIS, TMBR, EVLO, APTX, MGTA, ABVC, NLTX, CTMX, ASMB, TIL, NUVB, FWBI, SLRX, SABS, VCNX, GOVX, CKPT, CLRB, FBIO, PTN, QLGN, SLNO

*Chart delayed

Analyzing fundamentals for ALRN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ALRN Fundamentals page.

Watching at ALRN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ALRN Technicals page.